相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Analysis of progression-free survival in oncology trials: Some common statistical issues
Kevin J. Carroll
PHARMACEUTICAL STATISTICS (2007)
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
Tomohide Tamura et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
Shanu Modi et al.
CLINICAL BREAST CANCER (2006)
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
Bhuvaneswari Ramaswamy et al.
CLINICAL CANCER RESEARCH (2006)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden et al.
ANNALS OF ONCOLOGY (2005)
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
A Polychronis et al.
LANCET ONCOLOGY (2005)
A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
G Atalay et al.
ANNALS OF ONCOLOGY (2003)
分享论文
